La vendita allo scoperto per Raytech Holding dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Raytech Holding. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Raytech Holding (NASDAQ:RAY) Azioni, Report sulle vendite allo scoperto

Raytech Holding

Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.

Raytech Holding Limited - ordinary shares

Raytech Holding Ltd

Raydium - United States Dollar

Erayak Power Solution Group Inc. - Class A Ordinary Shares

Erayak Power Solution Group Inc

Rayliant Quantamental China Equity ETF

The Advisors' Inner Circle Fund III Rayliant Quantitative Developed Market Equity ETF

Rayliant Quantamental Emerging Market ex-China Equity ETF

The Advisors' Inner Circle Fund III Rayliant SMDAM Japan Equity ETF

Global X Solar ETF

Rayont Inc

GLOBAL X SOLAR UCITS ETF

News

Guidance

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

Biotech

General

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

WIIM

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

Earnings

Earnings Beats

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Earnings Misses

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 Adj EPS guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 analyst estimate. Lowers FY2024 sales outlook from $825.00 million-840.00 million to $800.00 million-805.00 million vs $824.37 million estimate.

HLIO

Helios Technologies Lowers FY2024 Adj EPS Guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 Est; Lowers FY2024 Sales Guidance from $825.00M-840.00M to $800.00M-805.00M vs $824.37M Est

MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. The company reported quarterly sales of $797.000 million which beat the analyst consensus estimate of $794.160 million by 0.36 percent. This is a 10.25 percent decrease over sales of $888.000 million the same period last year.

MRC Global Q3 2024 Adj. EPS $0.22 Beats $0.20 Estimate, Sales $797.000M Beat $794.160M Estimate

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 GAAP EPS guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 analyst estimate..

Helios Technologies Lowers FY2024 GAAP EPS Guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 Est

Supermicro Sees Q2 FY2025 Net Sales $5.5B-$6.1B, GAAP EPS $0.48-$0.58, Non-GAAP EPS $0.56-$0.65

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is unchanged from the same period last year. The company reported quarterly sales of $150.50 million which missed the analyst consensus estimate of $152.30 million by 1.18 percent. This is a 6.40 percent decrease over sales of $160.78 million the same period last year.

SWIM

Latham Group Q3 EPS $0.05 Misses $0.06 Estimate, Sales $150.50M Miss $152.30M Estimate

QLYS

Qualys Raises 2024 Adj EPS Guidance From $5.46- $5.62 To $5.81 - $5.91 (Est $5.57), Lifts Revenue Guidance From $597.5M - $601.5M To $602.9M - $605.9M (Est $599.362M)

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) affirms FY2025 sales outlook from $815.00 million-865.00 million to $815.00 million-865.00 million.

INNV

InnovAge Holding Affirms FY2025 Sales Guidance to $815.00M-865.00M  VS Est. 844.27M

Microchip Sees Q3 2024 Net Sales $1.025B-$1.095B

trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.02 by 300 percent. The company reported quarterly sales of $160.565 million which beat the analyst consensus estimate of $154.280 million by 4.07 percent. This is a 6.55 percent decrease over sales of $171.825 million the same period last year.

TRVG

trivago Q3 2024 GAAP EPS $(0.04) Misses $0.02 Estimate, Sales $160.565M Beat $154.280M Estimate

IPO Roundup: Ryde Group, SolarJuice, and more

IPO Roundup: Games Global, RF Acquisition, and more

Raytech Holding Limited (RAY) has released an update. Raytech Holding Limited has entered into an underwriting agreement with Revere Securities LLC...

Raytech Holding Announces New Share Offering

U.S. IPO Weekly Recap: Hot Pot Chain Leads The Week's IPOs As The Pipeline Gets A Billion-Dollar Boost

Sea, DraftKings, Sasol among premarket losers' pack

Wall Street Breakfast: The Week Ahead

Raytech announces a rise in 2024 revenue

Raytech Holding Limited (RAY) has released an update. Raytech Holding Limited, a Hong Kong-based personal care electrical appliance company, has an...

Raytech Seals IPO Over-Allotment, Boosts Capital

Raytech Holding Limited (RAY) has released an update. Raytech Holding Limited has announced its upcoming annual shareholder meeting scheduled for O...

Raytech Holding Announces Upcoming Shareholder Meeting

Raytech Holding Limited (RAY) has released an update. Raytech Holding Limited has introduced its 2024 Equity Incentive Plan aimed at enhancing long...

Raytech Holding Limited Launches 2024 Equity Incentive Plan

AAPL

ADBE

AKAN

AMDI

AMZN

APRI

AVGO

BCTX

BTOC

CASY

CVGW

CYTO

DKNG

FCEL

GALE

GROY

HLIT

INTJ

JDZG

KDLY

KNOP

LGCL

LICN

MINM

MLGO

MRAI

NRDY

NTHI

NVDA

ONMD

ORCL

PAVS

PLAY

PLCE

QRVO

RBRK

RDDT

RFAIU

RNAZ

RSHL

RYDE

SHIM

SPHIF

SPWR

STLA

SUNH

SWIN

TSLA

YEXT

Press Releases

Raytech Holding Limited Announces Pricing of Its Initial Public Offering

Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market

Raytech Holding Limited Announces Closing of $6 Million Initial Public Offering

Raytech Holding Pre-announces Preliminary Key Financial Matric for 2024

Raytech Holding Limited Announces Closing of the Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

Raytech Holding Reports Financial Results for Fiscal Year Ended March 31, 2024

Raytech Holding Limited Announces Results of 2024 Annual Meeting of Shareholders

Comments

Raytech Holding

Vendite allo scoperto

Raytech Holding (NASDAQ:RAY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO